Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 343

Sort by

Sort Order Select

Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi

Blood (2024) 144 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2024-200204

Published: 2024

Journal Articles

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2024-208300

Published: 2024

Journal Articles

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Michael Wang, Patrick Connor Johnson, Salim Yazji, Yisrael Katz, Angela Pietrofeso, James Robinson, Matthew Mei, Matthew J. Frigault, James B. Breitmeyer, Caron A. Jacobson

Blood (2024) 144 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2024-200998

Published: 2024

Journal Articles

Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Rudra Prasad Dutta, Heng-Huan Lee, Ravi Prakash Shukla, Violetta V Leshchenko, Fanye Meng, Fangfang Yan, Yang Liu, Husnu Kaniskan, Jian Jin, Lapo Alinari, Michael Wang, Samir Parekh

Blood (2024) 144 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2024-210591

Published: 2024

Journal Articles

Mim8 Prophylaxis Beyond Bleeding: Investigating Multifaceted, Patient-Reported Outcomes for Hemophilia A in the FRONTIER2 Study

Cedric Hermans, Cihan Ay, Carmen Escuriola, Peter Kampmann, Rikke Medom Meldgaard, Ilgiz Rakhmatullin, Ciprian Tomuleasa, Lize Fie Ditteke van Vulpen, Michael Wang, Irena Woźnica-Karczmarz, Sophie Susen

Blood (2024) 144 (Supplement 1): 1212.

https://doi.org/10.1182/blood-2024-198395

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Evaluating Full Antitumor Activities of Monoclonal Antibody and Innate Immune Cells in Relapsed/Refractory Mantle Cell Lymphoma Using Ex Vivo Organoid Platform

Lei Nie, Vivian Jiang, Yang Liu, Tianci Zhang, Hong Kim, Jovanny Vargas, Qingsong Cai, Selvi Thirumurthi, David Santos, Michael Wang

Blood (2024) 144 (Supplement 1): 2994.

https://doi.org/10.1182/blood-2024-208895

Published: 2024

Journal Articles

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Blood (2024) 144 (Supplement 1): 4388.

https://doi.org/10.1182/blood-2024-198018

Published: 2024

Journal Articles

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Blood (2024) 144 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2024-207616

Published: 2024

Journal Articles

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2024-200290

Published: 2024

Journal Articles

Orally Effective CDK9 Inhibitor YX0798 for Treating Aggressive Lymphoma

Vivian Jiang, Yu Xue, Hong Kim, Qingsong Cai, Tianci Zhang, Lei Nie, Joseph McIntosh, Yang Liu, Haiyan Chen, David Santos, Selvi Thirumurthi, Jia Zhou, Michael Wang

Blood (2024) 144 (Supplement 1): 7474.

https://doi.org/10.1182/blood-2024-207657

Published: 2024

Journal Articles

FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A

Guy Young, Katherine Eakle, Elise Lim, Michael Wang

Blood (2024) 144 (Supplement 1): 2589.

https://doi.org/10.1182/blood-2024-193816

Published: 2024

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Hun Ju Lee, Gregory Ravizzini, Eslam Aboismail, Jenna Wixom, Jared Henderson, Luis E. Fayad, Sairah Ahmed, Ranjit Nair, Jason R. Westin, Swaminathan P Iyer, Chijioke Nze, Ajlan Al Zaki, Francisco Vega, Michael Wang, Christopher R. Flowers, Luis Malpica

Blood (2024) 144 (Supplement 1): 1674.3.

https://doi.org/10.1182/blood-2024-212005

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma

Margaret Elizabeth Simmons, Joseph McIntosh, Tianci Zhang, Yijing Li, Fangfang Yan, Yixin Yao, Lei Nie, Heng-Huan Lee, Wei Wang, Vivian Changying Jiang, Michael Wang, Yang Liu

Blood (2023) 142 (Supplement 1): 5789.

https://doi.org/10.1182/blood-2023-187405

Published: 2023

NARROW

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Mim8 Prophylaxis Beyond Bleeding: Investigating Multifaceted, Patient-Reported Outcomes for Hemophilia A in the FRONTIER2 Study

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Evaluating Full Antitumor Activities of Monoclonal Antibody and Innate Immune Cells in Relapsed/Refractory Mantle Cell Lymphoma Using Ex Vivo Organoid Platform

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Orally Effective CDK9 Inhibitor YX0798 for Treating Aggressive Lymphoma

FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only